EPW
VRTX icon

Evolve Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Evolve Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Buy
1,083
+428
+65% +$190K 0.03% 485
2026
Q1 		$292K Buy
+655
New +$305K 0.02% 794

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Evolve Private Wealth's VRTX Position: Q2 2026 in Review

Evolve Private Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 65% in Q2 2026, buying an estimated $190K and bringing the position to 1,083 shares worth $538K. The position accounts for 0.03% of the portfolio, ranked #485.

Evolve Private Wealth first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Evolve Private Wealth held 1,083 shares of Vertex Pharmaceuticals worth $538K as of Q2 2026.
  • Evolve Private Wealth bought 428 Vertex Pharmaceuticals shares in Q2 2026, an estimated $190K.
  • Vertex Pharmaceuticals made up 0.03% of Evolve Private Wealth's portfolio in Q2 2026, its #485 holding.
  • Evolve Private Wealth first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.